Karius
Latest round
- Series C
Last raised
- May 2024
Total raised
- $330M
Investors
- 14
About Karius
, and Tim Blauwkamp, Karius, Inc. operates as a life sciences company that focuses on the treatment of infectious diseases. In May 2024, Karius, Inc. The company provides a wide range of diagnostic products, such as the Karius Test, a microbial liquid biopsy for infectious diseases. Additionally, the firm also provides services such as clinical metagenomic next-generation sequencing (mNGS) and AI-driven analysis for rapid pathogen detection and treatment optimization.
Who invested in Karius
14 investors across 6 rounds
See all investors in Karius
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Karius
Who invested in Karius?
Karius has 14 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Karius raised?
Karius has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Karius last raise money?
Karius's most recent round on record is a Series C, in May 2024.
What does Karius do?
, and Tim Blauwkamp, Karius, Inc.
Where is Karius headquartered?
Karius is headquartered in Redwood City, US.
Which VCs invest in companies like Karius?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Karius's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Karius? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.